哌柏西利胶囊致QT间期延长1例分析

doi:10.19803/j.1672-8629.20210977

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (2): 215-218.
DOI: 10.19803/j.1672-8629.20210977

哌柏西利胶囊致QT间期延长1例分析

冉拓耀¹, 李超^2*

¹重庆市公共卫生医疗救治中心药学部,重庆 400036;
²重庆大学附属肿瘤医院药学部,重庆 400030

收稿日期:2021-11-09 出版日期:2023-02-15 发布日期:2023-02-17
通讯作者: ^*李超,女,博士,主管药师,临床药学。E-mail：lichaolucy@sina.com
作者简介:冉拓耀,女,硕士,主管药师,临床药学。
基金资助:
重庆市科卫联合医学科研项目（2023QNXM041）; 重庆市临床药学重点专科建设项目

Analysis of one case of QT prolongation induced by palbociclib capsules

RAN Tuoyao¹, LI Chao^2*

¹Chongqing Public Health Medical Center, Chongqing 400036, China;
²Chongqing University Cancer Hospital, Chongqing 400030, China

Received:2021-11-09 Online:2023-02-15 Published:2023-02-17

摘要/Abstract

摘要： 目的对哌柏西利胶囊引起QT间期延长的病例进行分析,为临床合理用药提供参考。方法报道乳腺癌多发转移的女性患者接受细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制剂（哌柏西利）后出现QT间期延长1例。结果与结论 哌柏西利引起患者QT间期延长的可能原因包括个体差异、合并使用其他药物、食物等,提示临床不能忽视该药物使用期间心脏毒性相关的药学监护,关注食物或其他药物成分对肝药酶的影响,监测相关血药浓度,以减少不良反应的发生。

关键词: CDK4/6抑制剂, 哌柏西利, QT间期延长, 药品不良反应

Abstract: Objective To analyze one case of QT interval prolongation caused by palbociclib capsules in our hospital so as to provide reference for clinical rational drug use. Methods To report a case of QT prolongation in a breast cancer patient receiving cyclin-dependent kinase 4/6 (CDK4/6) inhibitor (palbociclib). Results and Conclusion Palbociclib may cause QT prolongation because of individual differences or combined use with other drugs or foods, so pharmaceutical care related to cardio toxicity during medication is required, and the effect of foods or other drug components on liver drug enzymes deserves attention. If possible, blood drug concentrations should be monitored to reduce adverse reactions.

Key words: CDK4/6 inhibitor, palbociclib, QT prolongation, adverse drug reaction

中图分类号:

冉拓耀, 李超. 哌柏西利胶囊致QT间期延长1例分析[J]. 中国药物警戒, 2023, 20(2): 215-218.

RAN Tuoyao, LI Chao. Analysis of one case of QT prolongation induced by palbociclib capsules[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 215-218.

参考文献

[1] Breast Cancer Expert Committee of National Cancer Quality Control Center, Cancer Drug Clinical Research Committee of China Anti-Cancer Association. Consensus recommendations for the clinical application of cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer[J]. Chinese Journal of Oncology(中华肿瘤杂志), 2021, 43(4): 405-413.
[2] HORTOBAGYI GN, STEMMER SM, BURRIS HA, et al.Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib plus letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer[J]. Ann Oncol, 2018, 29(7): 1541-1547.
[3] TRIPATHY D, IM SA, COLLEONI M, et al.Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial[J]. Lancet Oncol, 2018, 19(7): 904-915.
[4] YAP YG, CAMM AJ.Drug induced QT prolongation and torsades de pointes[J]. Heart, 2003, 89(11): 1363-1372.
[5] National Cencer for ADK Monitoring, China. The UK warns that CDK4/6inhibitors can cause interstitial lung disease and pneumonia[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(10): 1000.
[6] SANTONI M, OCCHIPINTI G, ROMAGNOLI E, et al.Different cardiotoxicity of palbociclib and ribociclib in breast cancer: gene expression and pharmacological data analyses, biological basis, and therapeutic implications[J]. BioDrugs, 2019, 33(6): 613-620.
[7] SLAMON DJ, NEVEN P, CHIA S, et al.Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3[J]. J Clin Oncol, 2018, 36(24): 2465-2472.
[8] BALL S, SWARUPS, SULTAN A, et al.Increased risk of cardiac conduction abnormalities with ribociclib in patients with metastatic breast cancer: a combined analysis of phase III randomized controlled trials[J]. Hematol Oncol Stem Cell Ther, 2021, 14(3): 260-262.
[9] GROENLAND SL, MARTÍNEZ-CHÁVEZ A, VAN DONGEN MGJ, et al. Clinical pharmacokinetics and pharmacodynamics of the cyclin-dependent kinase 4 and 6 inhibitors palbociclib, ribociclib, and abemaciclib[J]. Clinical Pharmacokinetics, 2020, 59(12): 1501-1520.
[10] BRAAL CL, JONGBLOED EM, WILTING SM, et al.Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences[J]. Drugs, 2021, 81(3): 317-331.
[11] DURAIRAJ C, RUIZ-GARCIA A, GAUTHIER ER, et al.Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer[J]. Anticancer Drugs, 2018, 29(3): 271-280.
[12] BEACHLER DC, DE LUISE C, JAMAL-ALLIAL A, et al.Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study[J]. BMC Cancer, 2021, 21(1): 97.
[13] KNEZHRNČIČ M, IVANOVSKI M, CÖRD, et al. Chia seeds (Salvia Hispanica L.): an overview-phytochemical profile, isolation methods, and application[J]. Molecules, 2019, 25(1): 11.
[14] YANG XF, WANG NP, ZENG FD.Effects of active components of traditional Chinese medicine on drug metabolism enzymes[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2002, 27(5): 325-327.
[15] HORN JR, HANSTEN PD, CHAN LN.Proposal for a new tool to evaluate drug interaction cases[J]. Ann Pharmacother, 2007, 41(4): 674-680.
[16] REN XY, CONG MH.Food and drug interactions: a general review[J]. Electron J Metab Nutr Cancer(肿瘤代谢与营养电子杂志), 2019, 6(1): 7-12.

哌柏西利胶囊致QT间期延长1例分析

Analysis of one case of QT prolongation induced by palbociclib capsules

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.